Corona Remedies IPO Allotment update: GMP signals 29% listing pop — Check steps to track status online using PAN details

According to experts, Corona Remedies shares are expected to list at a decent gain, and the stock may list with a premium of around ₹265 and ₹285 per share.

The GMP of Corona Remedies' IPO today is ₹305, indicating that the grey market is expecting the shares to list at ₹1,367. This means the grey market is expecting around 29% listing gain for the lucky allottees.

According to market observers, shares of the company are available at a premium of ₹305 per share, which is ₹10 higher than yesterday's Corona Remedies IPO GMP of ₹295.

For convenience, applicants can log in at the direct BSE link — bseindia.com/investors/appli_check.aspx or at the direct Bigshare Services link — ipo.bigshareonline.com/IPO_Status.html and check the Corona Remedies IPO allotment status online.

Applicants can log in at the direct BSE link — bseindia.com/investors/appli_check.aspx — and check Corona Remedies IPO allotment status online.

To check one's share allotment status online using PAN details, the applicant must log in to the Bigshare Services website. In the selection type, they need to choose the PAN Number.

To check the Corona Remedies IPO allotment status using PAN details, you need to log in to the Bigshare Services website. After logging in, they need to select Corona Remedies Limited, select the PAN number in the Selection Type, enter the CAPTCHA, and click on the submit button. Your allotment status will become available on your computer monitor or cell phone screen.

An applicant can check one's share allotment status online by using one's PAN details. However, they will have to login at the website of official registrar Bigshare Services.

In the last two days, the Corona Remedies IPO GMP has risen from ₹270 to ₹305. The company's shares have been continuously attracting positive sentiments since the closure of the public issue.

The public issue is proposed for listing on the NSE and the BSE. The most likely Corona Remedies IPO listing date is 15 December 2025 i.e. Monday next week.

The Corona Remedies IPO allotment status can be checked online by logging in to the BSE website (bseindia.com) or the registrar's website, Bigshare Services(bigshareonline.com). For more convenience, they can log in at the direct BSE link — bseindia.com/investors/appli_check.aspx or at the direct Bigshare Services link — ipo.bigshareonline.com/IPO_Status.html and check the Corona Remedies IPO allotment status online.`

1] Log in at the direct Bigshare Services link — bigshareonline.com;

2] Go to Server-1 and select 'Corona Remedies Ltd' in the company name space;

3] Select either of 'Application No./CAF No., Beneficiary ID or PAN details';

4] Enter CAPTCHA; and

5] Click on the 'Search' option.

Your Corona Remedies IPO allotment status will appear on the screen of your desktop, laptop, or cell phone.

One can check the Corona Remedies IPO allotment status online by following the step-by-step guide:

1] Log in at the direct BSE link: bseindia.com/investors/appli_check.aspx;

2] Select 'Equity' in the Issue Type option;

3] Select 'Corona Remedies Ltd' in the Issue Name;

4] Enter 'Application Number' or PAN card details;

5] Click on the BOX before 'I'm not a robot'; and

6] Click on the 'Search' option.

Your Corona Remedies IPO allotment status will appear on the screen of your desktop, laptop, or cell phone.

Applicants can check the Corona Remedies IPO allotment online by logging in to the BSE website (bseindia.com) or the Bigshare Services website (bigshareonline.com). For more convenience, they can log in at the direct BSE link — bseindia.com/investors/appli_check.aspx or at the direct Bigshare Services link — ipo.bigshareonline.com/IPO_Status.html and check the Corona Remedies IPO allotment status online.`

According to market observers, shares of the company are available at a premium of ₹305 in the grey market today, which is ₹10 higher than Corona Remedies IPO GMP of ₹295.

Those who have applied for the public issue can check their application status online by logging in at the BSE website — bseindia.com or at the Bigshare Services website — bigshareonline.com.

Corona Remedies IPO Allotment LIVE: Investors who are looking to check their share allotment status for the Corona Remedies IPO can check their status on the registrar Bigshare Services website by following the steps below —

Step 1. Open the Bigshare Services website or follow this direct link — https://ipo.bigshareonline.com/ipo_status.html

Step 2. Enter any of the three servers and select “Corona Remedies Ltd” company name in the dropdown.

Step 3. Select either “Application No./CAF No. or Beneficiary ID or PAN details”

Step 4. Enter the security captcha

Step 5. Select the “Search” option to check the share allotment status of your Corona Remedies bid.

Corona Remedies IPO Allotment LIVE: Investors who are looking to check their share allotment status for the Corona Remedies IPO can check their status on the BSE website by following the steps mentioned below —

Step 1. Open the BSE website IPO allotment section or follow the link below
Direct link here: https://www.bseindia.com/investors/appli_check.aspx

Step 2. Select the ‘Equity’ option under the Issue Type category mentioned on the page.

Step 3. Select the company name “Corona Remedies Ltd” under the Issue Name section.

Step 4. Enter your IPO “Application Number” or “PAN card” details on the website.

Step 5. After completing the security captcha, select the “Search” option to check the share allotment of your Corona Remedies IPO.

Corona Remedies IPO Allotment LIVE: Investors who are looking to check their share allotment status for the Corona Remedies IPO can check their status on the NSE website. Here's how to check —

Step 1. Open the NSE website or follow the direct link here — https://www.nseindia.com/invest/check-trades-bids-verify-ipo-bids

Step 2. Select the “Equity & SME IPO bid details” on the portal.

Step 3. Select “Corona Remedies (CORONA)” from the dropdown menu.

Step 4. Enter your PAN ID along with your IPO Application Number

Step 5. Click on “Submit” to check the allotment status of Corona Remedies IPO.

Corona Remedies IPO Allotment LIVE: As of 11 December 2025, the grey market premium of Corona Remedies IPO stands at ₹295 per share. With the upper price band at ₹1,062 per share, the company's stock is set to be listed at ₹1,357 apiece, marking a 28% potential listing gain, according to IPO India data.

Grey market premium (GMP) is an indicator which shows the investors' willingness to put their money into a public issue.

Corona Remedies’ brand-building strength is evident in its portfolio of 27 “engine” brands, which contributed 72.34% of domestic sales in MAT June 2025 and grew at a robust 20.68% CAGR from MAT June 2022 to MAT June 2025.

These brands include leading names such as Cor, Trazer, Cor9, B-29 and Myoril, with 12 of them ranking within the top five in their categories, underscoring the company’s sustained capability to scale brands across high-growth therapeutic areas.

The company has emerged as the second fastest growing among the top 30 pharmaceutical players in the Indian market between MAT (Moving Annual Turnover) June 2022 and MAT June 2025, outpacing the IPM with a strong domestic sales CAGR of 16.77% versus the industry’s 9.21%.

The company benefits from backward integration through La Chandra Pharmalab, an EU GMP and WHO GMP-certified hormone API manufacturer in Gujarat. It holds a right of first refusal for hormone APIs, an advantage given the complexity of hormonal drug production.

The company has delivered a robust financial trajectory, with topline expanding from ₹884 crore in FY23 to ₹1,196 crore in FY25, reflecting a 16.3% CAGR.

Profitability has scaled meaningfully, with EBITDA rising from ₹135 crore to ₹246 crore (35% CAGR) and PAT increasing from ₹85 crore to ₹149 crore (32% CAGR) over the same period.

As of June 2025, the company operated through 2 manufacturing facilities based in Bhayla, Gujarat and Solan, Himachal Pradesh, which have a 11 production lines with aggregate installed capacity of 1,285 million units per annum.

The facility in Bhayla is EU-GMP and WHO-GMP certified, while the Solan facility is WHO-GMP certified, portraying the company’s focus on quality manufacturing facilities.

Further, the company has invested in La Chandra Labs which also operates EU-GMP and WHO-GMP certified API manufacturing facility, which is used for backward integration of hormone-based women’s health products.

Strategic brand acquisitions and in-licensing remain central to its growth strategy. The acquisition of Myoril from Sanofi in FY24 strengthened the pain management portfolio, while earlier acquisitions of Vitneurin, Stelbid, Dilo DX/BM, Obimet, and Thyrocab enhanced the company’s presence in VMN, respiratory, gastroenterology, diabetes, and thyroid therapy areas.

In-licensing partnerships with global players such as Ferring Pharmaceuticals have further expanded offerings in women’s health and urology.

Overall, the company has established a scalable platform anchored by strong brands, specialist-focused marketing, robust manufacturing and R&D capabilities, and a proven track record of sustained outperformance versus the IPM.

• Second fastest-growing company within the top 30 pharmaceutical companies in the Indian pharmaceutical market
• Capabilities to build a diversified portfolio, including “engine” brands, in the targeted therapy areas
• Pan-India sales network and a marketing strategy focused on the “middle of the pyramid” target market
• Quality- and current Good Manufacturing Practices–focused manufacturing facilities, with strong research and development capabilities
• Qualified, experienced, and entrepreneurial management team supported by marquee investors

The company’s superior performance is rooted in its focus on high-margin chronic and sub-chronic segments, which account for 70.1% of domestic sales and have grown rapidly (20.48% CAGR over the same period). It has approximately 27 core “engine” brands, which contribute around 72% of domestic sales during MAT June 2025. These “engine” brands include market-leading names such as Cor, Trazer, Cor9, B-29, and Myoril during MAT June 2025.

Further, around 68% of the company’s sales are derived from therapy segments such as women’s health, cardio-diabeto, pain, and urology, which grew at a combined CAGR of approximately 22.4% between MAT June 2022 and MAT June 2025.

— Nirma Bang

As of Financial Year 2025, the Indian domestic formulation market, with a market size of approximately ₹2.3 trillion, accounted for around 2% of the global pharmaceutical market. India possesses a strong ecosystem to develop and manufacture pharmaceuticals, supported by state-of-the-art facilities and skilled technical manpower.

The domestic market (consumption) recorded a healthy CAGR of 9% between Financial Years 2020 and 2025. It is expected to grow at a CAGR of 8–9%, reaching ₹3.3–3.5 trillion by Financial Year 2030, driven by rising incidences of chronic diseases, as well as increasing awareness and access to quality healthcare.

Therapeutic & Engine brand concentration: During FY23/FY24/FY25/1QFY26, the company derived 56.0% / 60.4% / 62.4% / 65.1% of its revenue, respectively, from Women’s Health, Cardio-Diabetic and Pain Management therapeutic areas. Further, it derived 65.5% / 67.7% / 72.5% / 72.3% of its FY23/FY24/FY25/1QFY26 revenue from its 27 engine brands.

Geographical concentration: During FY23/FY24/FY25/1QFY26, the company derived 96.4% / 96.6% / 96.3% / 96.3% of its revenue from the domestic market, respectively. Any decrease in demand for the company’s products in India or any inability to expand into international markets may have an adverse impact on the company’s performance.

Raw material sourcing: The company depends entirely on third-party suppliers for raw materials and does not enter into any long-term contracts with these suppliers. Any failure to procure raw materials in a timely or cost-effective manner may have an adverse impact on the company’s performance.

As of June 2025, Corona Remedies operated through a robust distribution network comprising 22 C&F agents and over 2,000 distributors across 22 States and Union Territories in India. This network is further supported by a growing field force of 2,671 medical representatives, enabling the company to engage with specialist and super-specialist healthcare professionals, who together contributed approximately 75.8% of its prescription volume as of MAT June 2025.

According to the Crisil Intelligence Report, Corona Remedies is the second fastest growing firm among the top 30 companies in the Indian pharmaceutical market in terms of domestic sales performance from Moving Annual Total (MAT) June 2022 to June 2025. During the period, the company's domestic sales grew at a Compound Annual Growth Rate (CAGR) of 16.77 per cent compared to the IPM which grew at a CAGR of 9.21 per cent.

• Expand hospital network into new geographies
• Increase and diversify pharmaceutical product portfolio
• Upgrade technology, diagnostics, and medical infrastructure
• Strengthen operational efficiency in manufacturing
• Build stronger organizational and management systems
• Enhance community healthcare programs to improve brand goodwill

The company operates a diversified portfolio of 71 brands, with a strong emphasis on chronic and sub-chronic therapy areas, which together account for more than 70% of domestic revenue. Growth is anchored by 27 engine brands that contribute over 72% of domestic sales, including leadership brands such as Myoril, COR, and Trazer. Therapy exposure is well-distributed across Women’s Health, Cardio-diabeto, Pain Management, and Urology.

Financially, the company reported FY25 revenue of ₹1,196.4 crore, reflecting 17.9% year-on-year growth. EBITDA stood at ₹240 crore, an increase of 55.1% YoY, while PAT rose to ₹149.4 crore, registering 65.1% YoY growth. This strong performance was supported by improved margins.

Corona Remedies operates two R&D facilities in India, housed within its manufacturing units, both of which are registered with the Department of Scientific and Industrial Research, Ministry of Science and Technology. As of June 30, 2025, the company employed 103 personnel in its R&D department.

The company’s research and development initiatives are currently focused on multiple projects, including:

(i) new formulation development,

(ii) enhancing efficiencies in manufacturing processes,

(iii) packaging development, and

(iv) process engineering, among other areas.

Corona Remedies operates two manufacturing facilities located in the states of Gujarat (the Bhayla Manufacturing Facility) and Himachal Pradesh (the Solan Manufacturing Facility). The company is also in the process of commissioning a hormone manufacturing facility in Gujarat, which is expected to commence operations in the first quarter of Financial Year 2027.

Since the Corona Remedies IPO was entirely an offer for sale, no proceeds will be received by the company and will instead go to the selling shareholders. The company via the IPO looks to achieve the benefits of listing on the stock exchanges.

1. Head to NSE's website using this link: https://www.nseindia.com/invest/check-trades-bids-verify-ipo-bids
2. Select equity & SME IPO bid details
3. From the dropdown, select Corona Remedies
4. Enter PAN and Application Number
5. Hit Submit

1] Log in at the direct BSE link: bseindia.com/investors/appli_check.aspx

2] Select 'Equity' in the Issue Type option;

3] Select 'Corona Remedies Ltd' in the Issue Name;

4] Enter 'Application Number' or PAN card details;

5] Click on the BOX before 'I'm not a robot'; and

6] Click on the 'Search' option.

1] Log in at the direct Bigshare Services link — bigshareonline.com

2] Go to Server-1 and select 'Corona Remedies Ltd' in the company name space;

3] Select either of 'Application No./CAF No., Beneficiary ID or PAN details';

4] Enter captcha

5] Click on the 'Search' option.

The ₹655.37-crore Corona Remedies IPO received bids for 62.65 crore (62,65,41,440) equity shares against 45,71,882 shares on offer, according to the NSE data, resulting in 137.04 times bids.

The portion for Qualified Institutional Buyers (QIBs) was subscribed 278.52 times, while the quota for Non Institutional Investors received 208.88 times subscription. The Retail Individual Investors (RIIs) part subscribed 28.73 times.

Corona Remedies IPO grey market premium (GMP) remains robust today. As of today, the Corona Remedies IPO GMP is ₹295. This means that shares of Corona Remedies are trading ₹295 higher than the issue price of ₹1062. At the prevailing GMP, Corona Remedies IPO listing price would be ₹1357, a premium of 27.78%.